These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 32457345)

  • 1. Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations.
    Liu N; Yu M; Yin T; Jiang Y; Liao X; Tang J; Li Y; Qin D; Li D; Wang Y
    Signal Transduct Target Ther; 2020 May; 5(1):63. PubMed ID: 32457345
    [No Abstract]   [Full Text] [Related]  

  • 2. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
    Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
    Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
    Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
    Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
    Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
    Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal interstitial lung disease associated with AZD9291.
    Deng SM; Huang JA; Chen YB
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1227-S1229. PubMed ID: 30539877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of lung adenocarcinoma patients with malignant pleural effusion.
    Wu SG; Yu CJ; Tsai MF; Liao WY; Yang CH; Jan IS; Yang PC; Shih JY
    Eur Respir J; 2013 Jun; 41(6):1409-18. PubMed ID: 23018906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genomic imprint of cancer therapies helps timing the formation of metastases.
    Németh E; Krzystanek M; Reiniger L; Ribli D; Pipek O; Sztupinszki Z; Glasz T; Csabai I; Moldvay J; Szallasi Z; Szüts D
    Int J Cancer; 2019 Aug; 145(3):694-704. PubMed ID: 30694556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma.
    Kwok WC; Ho JCM; Tam TCC; Lui MMS; Ip MSM; Lam DCL
    Anticancer Drugs; 2019 Nov; 30(10):1048-1051. PubMed ID: 31584455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
    Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
    PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
    Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
    J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Li L; Jiang L; Wang Y; Zhao Y; Zhang XJ; Wu G; Zhou X; Sun J; Bai J; Ren B; Tian K; Xu Z; Xiao HL; Zhou Q; Han R; Chen H; Wang H; Yang Z; Gao C; Cai S; He Y
    Clin Cancer Res; 2019 Dec; 25(23):6967-6975. PubMed ID: 31413010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
    DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
    J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
    J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
    Tanaka H; Okamoto T; Shinyama M; Matsumura S; Fujii T
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):1067-9. PubMed ID: 23986053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
    Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
    Duan J; Xu J; Wang Z; Bai H; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Han J; Wang D; Tian Y; Yang Z; Zhang L; Chuai S; Ye J; Zhu G; Zhao J; Wu YL; Wang J
    J Thorac Oncol; 2020 Dec; 15(12):1857-1870. PubMed ID: 32916309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.